
No Recent Quote currently available

My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

Company Name	Symbol	%Change
STAAR SURGIC	STAA	10.98%
DTS INC	DTSI	6.89%
ANIKA THERAP	ANIK	6.04%
LUMOS NETWOR	LMOS	5.70%
INSTEEL IND	IIIN	5.28%

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Analyst Blog

Print

Share

BioScrip Reaffirmed at Neutral

by Zacks Equity Research

February 20, 2013 | Comments : 0 Recommended this article: (0)

RMD BIOS WAG GIVN

We maintain our long-term Neutral recommendation on BioScrip Inc. (BIOS - Analyst Report). Although the company has several positive catalysts to drive growth over the long haul, looming concerns keep us on the sidelines for this pharmacy benefit manager and infusion service provider.

Why the Reiteration?

BioScrip’s results in the most recent quarter surpassed the Zacks Consensus Estimate. While revenues shot up 27.3% year over year, adjusted earnings per share was in line with the year-ago results.

Following the divestment of pharmacy services business to Walgreens (WAG - Analyst Report), BioScrip increased its focus on its Infusion franchise. This is reflected in the recent acquisition of HomeChoice which will significantly boost revenue in the future. The buyout is expected to be accretive to BioScrip’s annual top-line by $70 million. However, we are apprehensive about integration risks.

While the company enjoys strong presence and competitive advantage in the Infusion and Home Health industry, the competitive landscape with larger players and deeper pockets remains unyielding. The competitive pressure also led to aggressive price wars in the last quarter. Consequently, margins remained under pressure.

The decline in Home Health reimbursement rates from certain government players also negatively impacted the company by creating a challenging operating environment. We note that BioScrip derived 33% of its revenues directly from Medicare, Medicaid or other government-sponsored healthcare programs in the third quarter. Reimbursement cuts are therefore a looming concern.

Based on these factors, estimates for 2013 for BioScrip have remained stagnant over the last 30 days. Accordingly, the stock carries a Zacks Rank #3 (Hold).

Other Stocks to Consider

We continue to monitor the future developments at BioScrip which might affect its financial results. Meanwhile, other medical stocks such as Given Imaging (GIVN), ResMed (RMD - Snapshot Report) and Medical Action (MDCI), carrying a Zacks Rank #1 (Strong Buy) are expected to do well in the near term.

We maintain our long-term Neutral recommendation on BioScrip Inc. (BIOS - Analyst Report). Although the company has several positive catalysts to drive growth over the long haul, looming concerns keep us on the sidelines for this pharmacy benefit manager and infusion service provider.

Why the Reiteration?

BioScrip’s results in the most recent quarter surpassed the Zacks Consensus Estimate. While revenues shot up 27.3% year over year, adjusted earnings per share was in line with the year-ago results.

Following the divestment of pharmacy services business to Walgreens (WAG - Analyst Report), BioScrip increased its focus on its Infusion franchise. This is reflected in the recent acquisition of HomeChoice which will significantly boost revenue in the future. The buyout is expected to be accretive to BioScrip’s annual top-line by $70 million. However, we are apprehensive about integration risks.

While the company enjoys strong presence and competitive advantage in the Infusion and Home Health industry, the competitive landscape with larger players and deeper pockets remains unyielding. The competitive pressure also led to aggressive price wars in the last quarter. Consequently, margins remained under pressure.

The decline in Home Health reimbursement rates from certain government players also negatively impacted the company by creating a challenging operating environment. We note that BioScrip derived 33% of its revenues directly from Medicare, Medicaid or other government-sponsored healthcare programs in the third quarter. Reimbursement cuts are therefore a looming concern.

Based on these factors, estimates for 2013 for BioScrip have remained stagnant over the last 30 days. Accordingly, the stock carries a Zacks Rank #3 (Hold).

Other Stocks to Consider

We continue to monitor the future developments at BioScrip which might affect its financial results. Meanwhile, other medical stocks such as Given Imaging (GIVN) and ResMed (RMD - Snapshot Report), carrying a Zacks Rank #1 (Strong Buy) are expected to do well in the near term.

Email Print Share Rate Pos Rate Neg

Disclosure / Disclaimer Link

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Username: Password:

Remember me [?]

Forgot Password

New Member

Recent Quotes

My Portfolio

More Zacks Resources

Zacks #1 Stocks on the Move 06/18/2013

Analyst Blog

BioScrip Reaffirmed at Neutral

by Zacks Equity Research